SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Roos Weil Damien)
 

Sökning: WFRF:(Roos Weil Damien) > (2017) > EGR2 mutations defi...

EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia

Young, Emma, 1990- (författare)
Uppsala universitet,Experimentell och klinisk onkologi,Richard Rosenquist Brandell
Noerenberg, Daniel (författare)
Department of Hematology, Oncology, and Tumor Immunology, Charité, University Medical Center, Berlin, Germany
Mansouri, Larry (författare)
Uppsala universitet,Experimentell och klinisk onkologi,Science for Life Laboratory, SciLifeLab,Richard Rosenquist Brandell
visa fler...
Ljungström, Viktor, 1986- (författare)
Uppsala universitet,Experimentell och klinisk onkologi,Science for Life Laboratory, SciLifeLab,Richard Rosenquist Brandell
Frick, Mareike (författare)
Department of Hematology, Oncology, and Tumor Immunology, Charité, University Medical Center, Berlin, Germany
Sutton, Lesley Ann (författare)
Karolinska Institutet,Uppsala universitet,Experimentell och klinisk onkologi,Science for Life Laboratory, SciLifeLab,Richard Rosenquist
Blakemore, Stuart James (författare)
Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK
Galan-Sousa, Joel (författare)
Department of Hematology, Oncology, and Tumor Immunology, Charité, University Medical Center, Berlin, Germany
Plevova, Karla (författare)
Central European Institute of Technology, Masaryk University and University Hospital Brno, Brno, Czech Republic
Baliakas, Panagiotis, 1977- (författare)
Uppsala universitet,Science for Life Laboratory, SciLifeLab
Rossi, Davide (författare)
Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy and Hematology, Oncology Institute of Southern Switzerland and Institute of Oncology Research, Bellinzona, Switzerland
Ruth, Clifford (författare)
Oxford National Institute for Health Research Biomedical Research Centre and Department of Oncology, University of Oxford, Oxford, UK
Roos-Weil, Damien (författare)
INSERM, U1170, Institut Gustave Roussy, Villejuif, France
Navrklova, Veronika (författare)
European Institute of Technology, Masaryk University and University Hospital Brno, Brno, Czech Republic
Dörken, Bernd (författare)
Department of Hematology, Oncology, and Tumor Immunology, Charité, University Medical Center, Berlin, Germany
Schmitt, Clemens A (författare)
Department of Hematology, Oncology, and Tumor Immunology, Charité, University Medical Center, Berlin, Germany
Ekström Smedby, Karin (författare)
Karolinska Institutet
Juliusson, Gunnar (författare)
Department of Laboratory Medicine, Stem Cell Center, Lund University, Lund, Sweden
Giacopelli, Brian (författare)
Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
Blachly, James (författare)
Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
Belessi, Chrysoula (författare)
Hematology Department, General Hospital of Nikea, Piraeus, Greece
Panayiotidis, Panayiotis (författare)
First Department of Propaedeutic Medicine, School of Medicine, University of Athens, Athens, Greece
Chiorazzi, Nicholas (författare)
Karches Center for Chronic Lymphocytic Leukemia Research, The Feinstein Institute for Medical Research, Manhasset, New York, USA
Davi, Frédéric (författare)
Laboratory of Hematology and Universite Pierre et Marie Curie, Hopital Pitie-Salpetriere, Paris, France
Langerak, Anton W (författare)
Department of Immunology, Laboratory for Medical Immunology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
Oscier, David (författare)
Department of Molecular Pathology, Royal Bournemouth Hospital, Bournemouth, UK
Schuh, Anna (författare)
Oxford National Institute for Health Research Biomedical Research Centre and Department of Oncology, University of Oxford, Oxford, UK
Gaidano, Gianluca (författare)
Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy
Ghia, Paolo (författare)
Università Vita-Salute San Raffaele, Milan, Italy and Division of Experimental Oncology and Department of Onco-Hematology, Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele Scientific Institute, Milan, Italy
Xu, Wei (författare)
Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center For Cancer Personalized Medicine, Nanjing, China
Fan, Lei (författare)
Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center For Cancer Personalized Medicine, Nanjing, China
Bernard, Olivier A (författare)
INSERM, U1170, Institut Gustave Roussy, Villejuif, France
Nguyen-Khac, Florence (författare)
Laboratory of Hematology and Universite Pierre et Marie Curie, Hopital Pitie-Salpetriere, Paris, France
Rassenti, Laura Z (författare)
Division of Hematology/Oncology, Department of Medicine, University of California at San Diego/Moores Cancer Center, La Jolla, CA, USA
Li, Jianyonglm (författare)
Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center For Cancer Personalized Medicine, Nanjing, China
Kipps, Thomas J (författare)
Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
Stamatopoulos, Kostas (författare)
Uppsala universitet,Experimentell och klinisk onkologi,Science for Life Laboratory, SciLifeLab,Department of Immunology, Genetics, and Pathology, Science for Life Laboratory, Uppsala University, Sweden and Institute of Applied Biosciences, Center for Research and Technology Hellas, Thessaloniki, Greece
Pospisilova, Sarka (författare)
Central European Institute of Technology, Masaryk University and University Hospital Brno, Brno, Czech Republic
Zenz, Thorsten (författare)
Department of Molecular Therapy in Haematology and Oncology (G250) and Department of Translational Oncology, National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Medicine V, University Hospital Heidelberg, Heidelberg, Germany and German Consortium for Translational Cancer Research (DKTK), Heidelberg, Germany
Strefford, Jonathan (författare)
Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK
Rosenquist, Richard (författare)
Karolinska Institutet,Uppsala universitet,Experimentell och klinisk onkologi,Science for Life Laboratory, SciLifeLab,Richard Rosenquist Brandell
Damm, Frederik (författare)
Department of Hematology, Oncology, and Tumor Immunology, Charité, University Medical Center, Berlin, Germany; German Consortium for Translational Cancer Research (DKTK), Heidelberg, Germany and Berlin Institute of Health (BIH), Berlin, Germany
Oakes, CC (författare)
visa färre...
 (creator_code:org_t)
2016-11-28
2017
Engelska.
Ingår i: Leukemia. - : Springer Science and Business Media LLC. - 0887-6924 .- 1476-5551. ; 31:7, s. 1547-1554
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Recurrent mutations within EGR2 were recently reported in advanced-stage chronic lymphocytic leukemia (CLL) patients and associated with a worse outcome. To study their prognostic impact, 2403 CLL patients were examined for mutations in the EGR2 hotspot region including a screening (n = 1283) and two validation cohorts (UK CLL4 trial patients, n = 366; CLL Research Consortium (CRC) patients, n = 490). Targeted deep-sequencing of 27 known/postulated CLL driver genes was also performed in 38 EGR2-mutated patients to assess concurrent mutations. EGR2 mutations were detected in 91/2403 (3.8%) investigated cases, and associated with younger age at diagnosis, advanced clinical stage, high CD38 expression and unmutated IGHV genes. EGR2- mutated patients frequently carried ATM lesions (42%), TP53 aberrations (18%) and NOTCH1/FBXW7 mutations (16%). EGR2 mutations independently predicted shorter time-to-first-treatment (TTFT) and overall survival (OS) in the screening cohort; they were confirmed associated with reduced TTFT and OS in the CRC cohort and independently predicted short OS from randomization in the UK CLL4 cohort. A particularly dismal outcome was observed among EGR2-mutated patients who also carried TP53 aberrations. In summary, EGR2 mutations were independently associated with an unfavorable prognosis, comparable to CLL patients carrying TP53 aberrations, suggesting that EGR2-mutated patients represent a new patient subgroup with very poor outcome.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Nyckelord

Oncology
Onkologi

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

  • Leukemia (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy